HIV virus (yellow) infecting a human cell. Credit: ZEISS Microscopy.

Janssen Pharmaceutical Companies and ViiV Healthcare UK have received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorisation of Juluca to treat HIV-1 infection.

Juluca is a single-pill, two-drug regimen consisting of 50mg of ViiV Healthcare’s dolutegravir and 25mg of rilpivirine manufactured by Janssen.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Dolutegravir is an integrase strand transfer inhibitor, while rilpivirine blocks non-nucleoside reverse transcriptase enzymes.

The recommendation covers the use of the drug in adults who are virologically suppressed and have been on a stable antiretroviral regimen for a minimum of six months and do not have a history of virological failure.

Janssen Research & Development global head Mathai Mammen said: “We are delighted to be one step closer to bringing Juluca to people living with HIV in Europe.

“This is an important milestone towards continuing to grow our portfolio of treatment options, to help meet the diverse and individual needs of people living with HIV.”

“Building on our 25-year commitment to make HIV history, this is an important milestone towards continuing to grow our portfolio of treatment options, to help meet the diverse and individual needs of people living with HIV.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The CHMP positive opinion comes after a review of findings from two Phase III clinical trials and a bioequivalence study.

Results from both trials demonstrated the non-inferiority of the dolutegravir/rilpivirine regimen in sustained virologic suppression through 48 weeks, compared to three and four drug combinations.

The dolutegravir and rilpivirine regimen was approved by the US Food and Drug Administration in November 2017 for the treatment of adults with HIV-1.

ViiV Healthcare UK has also submitted regulatory marketing applications for the regimen in Canada, Australia and Switzerland.